Search This Blog

Sunday, June 23, 2013

Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541 (NYSE:LLY)

Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541 (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.